Boudra R, Patenall BL, King S, Carter KA, Wang D, Best SA, Ko JY, Xu S, Fang R, Padilla MG, Schmults CD, Barthel SR, Lian CG, Ramsey MR. PRMT1 Inhibition Targets BNC1 – Dependent Proliferation in Squamous Cell Carcinoma. Journal of Investigative Dermatology. 2025;:10.1016/j.jid.2025.08.043
Drummond KJ, Spiteri M, Cain SA, Jones J, Shaya S, Topp M, Lu T, Tobler R, Valkovic AL, Moore Z, Fatunla OE, Kriel J, Moffet JJD, McAlpine H, Rosier M, Guan H, Dimou J, Schadewaldt V, Roberts-Thomson S, McArdle D, Lui E, Voelker-Albert M, di Sanzo S, Nijagal B, Narayana VK, Mitchell CB, Vissers JHA, Grimmond S, Rosenthal MA, Palmer LM, Best SA, Freytag S, Whittle JR. Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial. Nature Medicine. 2025;:10.1038/s41591-025-03884-4
O’Keeffe P, Nouri Y, Saw HS, Moore Z, Baldwin TM, Olechnowicz SWZ, Jabbari JS, Squire DM, Leslie S, Wang C, You Y, Ritchie ME, Cross RS, Jenkins MR, Audiger C, Naik SH, Whittle JR, Freytag S, Best SA, Hickey PF, Amann-Zalcenstein D, Bowden R, Brown DV. TIRE-seq simplifies transcriptomics via integrated RNA capture and library preparation. Scientific Reports. 2025;15(1):10.1038/s41598-025-98282-8
Whittle JR, Kriel J, Fatunla OE, Lu T, Moffet JJD, Spiteri M, Best SA, Freytag S. Spatial omics shed light on the tumour organisation of glioblastoma. Seminars in Cell and Developmental Biology. 2025;167:10.1016/j.semcdb.2024.12.006
Kay KE, Lee J, Hong ES, Beilis J, Dayal S, Wesley ER, Mitchell S, Wang SZ, Silver DJ, Volovetz J, Johnson S, McGraw M, Grabowski M, Lu T, Freytag L, Narayana VK, Freytag S, Best SA, Whittle JR, Wang Z, Reizes O, Yu JS, Hazen SL, Brown JM, Bayik D, Lathia J. Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition. Journal of Clinical Investigation. 2025;135(2):10.1172/jci177824
Whittle J, Rosenthal M, Spiteri M, Tobler R, Topp M, Cain S, Jones J, Shaya S, Valkovic A, Fatunla O, Dimou J, Roberts-Thomson S, McArdle D, Lui E, Nijagal B, Mitchell C, Grimmond S, Best S, Freytag S, Drummond K. CTNI-15. A PERIOPERATIVE STUDY OF SAFUSIDENIB IN PATIENTS WITH IDH1 MUTATED GLIOMA. Neuro-Oncology. 2024;26(Supplement_8):10.1093/neuonc/noae165.0382
Furst L, Roussel E, Leung R, George A, Li J, Best S, Whittle J, Cain J, Firestein R, Faux M, Eisenstat D. CNSC-36. REGULATION OF CELL FATE IN PAEDIATRIC HIGH-GRADE GLIOMA BY THE HOMEOBOX TRANSCRIPTION FACTOR DLX2. Neuro-Oncology. 2024;26(Supplement_8):10.1093/neuonc/noae165.0192
Cain SA, Topp M, Rosenthal M, Tobler R, Freytag S, Best SA, Whittle JR, Drummond KJ. A perioperative study of Safusidenib in patients with IDH1-mutated glioma. Future Oncology. 2024;20(33):10.1080/14796694.2024.2383064
Lu T, Freytag L, Moffet J, Kriel J, Whittle J, Freytag S, Best SA. OS07.5.A MULTI-MODAL EXAMINATION OF SPATIAL HETEROGENEITY IN THE ASTROCYTOMA MICROENVIRONMENT. Neuro-Oncology. 2024;26(Supplement_5):10.1093/neuonc/noae144.069
Whittle JR, Rosenthal M, Spiteri M, Cain S, Topp MD, Shaya S, Jones J, Valkovic A, Fatunla O, Dimou J, Tobler R, Roberts-Thomson S, McArdle D, Lui E, Nijagal B, Grimmond SM, Best SA, Freytag S, Drummond K. 443O A perioperative study of safusidenib in patients with IDH1 mutated glioma. Annals of Oncology. 2024;35:10.1016/j.annonc.2024.08.513
